Prostate MRI: What It Shows, PI-RADS Scores and What Happens Next

By Mr Neil Haldar, Consultant Urological Surgeon

---

In brief

A prostate MRI is often one of the first investigations offered when a PSA blood test is raised, or prostate cancer is otherwise suspected.

The scan can:

• show whether there is a suspicious area within the prostate;
• estimate how likely that area is to contain clinically significant cancer;
• help determine whether a biopsy is needed;
• guide the biopsy needle towards the most suspicious tissue;
• provide information about whether a confirmed cancer appears confined to the prostate;
• help plan surgery, radiotherapy, focal therapy or active surveillance.

A reassuring MRI can sometimes allow a man to avoid or defer an immediate biopsy. However, no scan is perfect. The MRI result must always be considered alongside the PSA level, PSA density, examination findings, family history and other individual risk factors.

---

Why might I be offered a prostate MRI?

The most common reason for requesting a prostate MRI is a raised prostate-specific antigen, or PSA, blood test.

PSA is produced by prostate cells. A raised PSA can occur for several reasons, including:

• benign enlargement of the prostate;
• inflammation or infection;
• recent ejaculation or instrumentation;
• urinary retention;
• prostate cancer.

A raised PSA does not therefore mean that you have cancer. Equally, PSA alone cannot reliably distinguish between harmless prostate conditions and a cancer that may require treatment.

MRI helps by providing a detailed picture of the prostate before any tissue is sampled. It allows the specialist team to look for suspicious areas and estimate whether a biopsy is likely to be helpful.

You may also be offered an MRI because of:

• an abnormal prostate examination;
• a rising PSA over time;
• a strong family history of prostate cancer;
• a previous negative biopsy despite continuing concern;
• known prostate cancer being managed with active surveillance;
• the need to assess a confirmed cancer before treatment.

---

What is a multiparametric prostate MRI?

MRI stands for magnetic resonance imaging. It uses a strong magnetic field and radio waves to create detailed images of the body. It does not use X-rays or ionising radiation.

A traditional MRI mainly shows anatomy. A multiparametric MRI, usually shortened to mpMRI, combines several types of image that provide different information about the prostate.

These commonly include:

T2-weighted images

These produce detailed pictures of the prostate’s anatomy. They help the radiologist assess:

• the size and shape of the gland;
• the different zones of the prostate;
• the prostate capsule;
• the seminal vesicles;
• structures close to the prostate.

T2-weighted images are particularly important when assessing the central or transition zone of the prostate, where benign enlargement commonly develops.

Diffusion-weighted images

Diffusion-weighted imaging examines how freely water molecules move through tissue.

Cancer cells are often packed more densely than normal prostate cells. This can restrict water movement and create a recognisable pattern on diffusion-weighted images and on the corresponding apparent diffusion coefficient, or ADC, map.

Diffusion imaging is particularly important when assessing the peripheral zone, where many prostate cancers develop.

Dynamic contrast-enhanced images

Some prostate MRI examinations include an injection of a gadolinium-based contrast agent into a vein.

The scan then observes how quickly different areas of the prostate take up the contrast. Cancer can sometimes develop abnormal blood vessels and show early focal enhancement.

Contrast is no longer the main determinant of most prostate MRI scores. Its principal role is often to clarify an uncertain finding, particularly in the peripheral zone.

---

Is contrast always required?

Not necessarily.

A full multiparametric MRI includes contrast-enhanced imaging. A biparametric MRI uses the T2-weighted and diffusion-weighted sequences without contrast.

Biparametric MRI has several possible advantages:

• the scan may be shorter;
• no intravenous injection is needed;
• there is no exposure to gadolinium;
• more scans may be performed within the available scanner time.

For many men undergoing an initial assessment, a well-performed biparametric MRI may provide the information required. However, contrast can still be valuable when:

• a finding is uncertain;
• the quality of another sequence is limited;
• the prostate has previously been treated;
• recurrence is suspected;
• more detailed treatment planning is required.

The most appropriate protocol depends on the clinical question, scanner quality, and local specialist practice.

---

What happens during a prostate MRI?

Before the scan, you will be asked about:

• metal implants;
• pacemakers or other electronic devices;
• previous surgery;
• kidney problems;
• allergies;
• possible reactions to contrast;
• claustrophobia.

You will usually be asked to remove metal objects and change into a gown.

During the scan, you lie on a table that moves into the MRI scanner. The scanner is open at both ends but can feel enclosed. It also makes loud knocking and buzzing noises. You will usually be given ear protection and may be able to listen to music.

It is important to remain as still as possible because movement can blur the images.

Depending on the centre, you may be asked to empty your bowels beforehand. Stool, rectal gas and bowel movement can interfere with some of the images, particularly the diffusion sequence. Some centres use a small enema or an antispasmodic medicine to reduce bowel movement, although preparation varies.

Most contemporary prostate MRI examinations use an external surface coil placed over the pelvis. An internal endorectal coil is now rarely required in routine UK practice.

The scan commonly takes about 30 to 45 minutes, although this varies by protocol.

---

Is a prostate MRI painful?

The scan itself should not be painful.

You will need to lie still on a relatively firm table, and some people find this uncomfortable. An intravenous cannula is required when contrast is used or when an antispasmodic medicine is given.

Tell the radiology department in advance if you are particularly anxious about confined spaces. Practical measures, reassurance and, in selected cases, medication may help.

---

How are prostate MRI results reported?

Radiologists usually describe the probability that an abnormal area contains clinically significant prostate cancer using a five-point scoring system.

Two related systems are commonly encountered:

• PI-RADS, which is widely used internationally;
• a Likert score, which is frequently used in UK practice.

Both use a scale from 1 to 5, although their underlying methods are not identical.

Score	General meaning
1	Clinically significant cancer is highly unlikely
2	Clinically significant cancer is unlikely
3	The finding is uncertain or equivocal
4	Clinically significant cancer is likely
5	Clinically significant cancer is highly likely

A score is not a diagnosis. Only a biopsy can confirm whether cancer is present and determine its microscopic grade.

---

What is a PI-RADS score?

PI-RADS stands for Prostate Imaging Reporting and Data System.

It provides radiologists with a standard framework for assessing suspicious prostate lesions. The score is based on:

• which part of the prostate contains the lesion;
• its appearance on the anatomical images;
• the degree of restricted diffusion;
• its size;
• whether there are signs of extension beyond the prostate;
• in certain situations, whether it shows early focal contrast enhancement.

In the peripheral zone, diffusion imaging most influences the score. In the transition zone, the T2-weighted anatomical appearance is usually the dominant feature.

The lesion with the highest PI-RADS category is generally designated the index lesion. When two lesions have the same score, features such as extension outside the prostate and lesion size help determine which is considered the index lesion.

---

What does a Likert score mean?

A Likert score is also a five-point assessment of how likely an area is to contain clinically significant prostate cancer.

Unlike the more rule-based PI-RADS system, the Likert assessment allows the reporting radiologist to incorporate the overall appearance of the scan and their expert clinical judgement.

In practical terms, patients may see reports using either system. A score of 1 or 2 is generally reassuring, 3 is uncertain, and 4 or 5 represents increasing concern.

The score must still be interpreted alongside your PSA, PSA density, examination findings and personal risk factors.

---

What is a PI-RADS or Likert 3 lesion?

A score of 3 is deliberately described as equivocal. It means the radiologist cannot confidently classify the finding as either benign or suspicious.

A score of 3 does not automatically mean that you need a biopsy. The decision will often depend on factors such as:

• your PSA level;
• your PSA density;
• whether the PSA is rising;
• your age and general health;
• your family history;
• your ethnicity and inherited risk;
• prostate examination findings;
• whether you have had a previous biopsy;
• the quality of the MRI;
• the precise appearance and location of the lesion.

Some men with a score of 3 will be advised to have a biopsy. Others may be monitored with repeat PSA testing, clinical review and, where appropriate, another MRI.

---

What is PSA density?

PSA density compares PSA levels with prostate size.

It is calculated by dividing PSA by prostate volume, which can usually be measured on MRI.

This is useful because a large benign prostate can produce more PSA than a small prostate. A moderately raised PSA may therefore be less concerning in a man with a very large prostate than in a man with a small gland.

PSA density is particularly helpful when deciding whether to perform a biopsy after:

• a reassuring MRI;
• a PI-RADS or Likert 3 result;
• a previous negative biopsy.

There is no single figure that should be interpreted in isolation. The result is used as part of an overall risk assessment.

---

Will I need a biopsy after the MRI?

Not everyone needs a biopsy after a prostate MRI.

A biopsy is more likely to be recommended when:

• the MRI shows a PI-RADS or Likert 4 or 5 lesion;
• a score 3 lesion is accompanied by other concerning features;
• the PSA density is elevated;
• the PSA continues to rise;
• the prostate examination is abnormal;
• there is a strong family or genetic risk;
• clinical concern remains despite a reassuring scan.

A biopsy may sometimes be avoided or deferred when:

• the MRI is reassuring;
• PSA density is low;
• examination findings are normal;
• there is no strong family history;
• the PSA pattern is not concerning;
• the scan is of good diagnostic quality.

The decision should be made through shared discussion. Avoiding an immediate biopsy usually means entering a planned follow-up pathway rather than ignoring the PSA.

---

What happens if my prostate MRI is normal?

A normal or reassuring MRI substantially reduces the chance that a clinically significant prostate cancer is present, but it does not reduce the risk to zero.

Some cancers can be difficult to see because they are:

• very small;
• diffusely infiltrating rather than forming a clear mass;
• located in a technically difficult area such as the apex;
• obscured by movement, rectal gas or metal-related artefact;
• not strongly different in appearance from the surrounding prostate tissue.

After a reassuring MRI, your specialist may recommend:

• repeating the PSA after an agreed interval;
• calculating or monitoring PSA density;
• repeating the prostate examination;
• reviewing any family or inherited risk;
• repeating the MRI if the PSA changes;
• proceeding to biopsy if clinical concern remains high.

A negative MRI should therefore be seen as reassuring evidence within a wider risk assessment, not as an absolute guarantee.

---

How does MRI guide a prostate biopsy?

Before MRI became routine, prostate biopsies were usually performed by taking a standard pattern of samples throughout the gland without knowing exactly where a cancer might be located.

MRI now allows the biopsy to be directed towards suspicious tissue.

There are several ways to target an MRI-visible lesion:

Cognitive targeting

The surgeon or radiologist studies the MRI and mentally maps the lesion onto the live ultrasound image used during the biopsy.

MRI–ultrasound fusion

Specialist software combines the previous MRI images with the real-time ultrasound scan. The suspicious area is displayed on the ultrasound screen to help guide the needle.

In-bore MRI biopsy

The biopsy is performed inside the MRI scanner under direct MRI guidance. This is available in selected centres but is less commonly used because it is more time-consuming and resource-intensive.

The accuracy of any approach depends partly on the operator’s experience and the quality of the imaging.

---

What is a transperineal prostate biopsy?

Most modern prostate biopsies in the UK are performed through the skin of the perineum—the area between the scrotum and anus.

This is called a transperineal biopsy.

An ultrasound probe is placed in the rectum to create an image of the prostate, but the biopsy needles pass through the perineal skin rather than through the rectal wall.

Advantages include:

• a lower risk of serious infection than with a transrectal biopsy;
• good access to the front and apex of the prostate;
• the ability to target MRI-visible lesions;
• the opportunity to sample other relevant areas of the gland.

Many transperineal biopsies can now be performed under local anaesthetic.

The specialist may take targeted samples from the MRI lesion, along with additional samples from the surrounding tissue or other areas of the prostate. This is because MRI and targeted biopsy are highly valuable, but neither is completely infallible.

---

Can MRI tell how aggressive a prostate cancer is?

MRI can estimate the likelihood that an abnormality represents clinically significant cancer. Features such as marked diffusion restriction, increasing lesion size and extension beyond the prostate may indicate more important disease.

However, MRI cannot determine the cancer grade with certainty.

A biopsy is required to examine the cells under a microscope and establish:

• whether cancer is present;
• the Gleason score;
• the Grade Group;
• the amount of cancer within the samples;
• whether particular pathological features are present.

MRI and biopsy therefore provide different but complementary information.

---

How is MRI used during active surveillance?

Active surveillance is a structured monitoring programme for men with prostate cancer that appears unlikely to cause harm in the near future.

The aim is to avoid or delay treatment—and its possible side effects—unless there is evidence that the cancer is becoming more significant.

MRI can help by:

• identifying the most important lesion at the start of surveillance;
• guiding confirmatory or repeat biopsy;
• showing whether a lesion has enlarged;
• detecting changes in its imaging characteristics;
• identifying a new suspicious lesion.

Radiologists may use the PRECISE framework to describe changes between MRI scans during active surveillance.

A stable MRI is reassuring, but it cannot always exclude microscopic progression. Decisions about repeat biopsy should also consider:

• PSA density;
• PSA changes over time;
• previous biopsy findings;
• the original cancer grade and volume;
• age and general health;
• how long the man has been on surveillance.

An apparent change on MRI will often lead to a targeted biopsy before a decision is made to move from surveillance to treatment.

---

How does MRI help plan prostate cancer surgery?

When prostate cancer has been confirmed, MRI can provide information about whether the disease appears confined to the prostate.

The radiologist looks for features such as:

• broad contact between the tumour and prostate capsule;
• irregularity or bulging of the capsule;
• a visible breach of the capsule;
• involvement of the seminal vesicles;
• possible involvement of the neurovascular bundles;
• enlarged or suspicious lymph nodes.

This information can influence surgical planning.

For example, if the cancer appears well clear of the nerves controlling erections, nerve-sparing surgery may be more feasible on that side. Where MRI suggests that cancer reaches or extends beyond the edge of the gland, a wider excision may be required to maximise the chance of removing the cancer completely.

MRI is better at identifying established extension outside the prostate than microscopic extension. The scan therefore informs surgical judgement but cannot predict the final pathology with complete certainty.

---

How does MRI help with radiotherapy and focal therapy?

MRI can help radiotherapy teams:

• define the prostate and surrounding anatomy;
• identify the dominant tumour;
• assess possible extension outside the gland;
• plan treatment volumes;
• reduce unnecessary exposure to nearby structures where possible.

MRI is also central to assessing and planning focal therapies such as high-intensity focused ultrasound and cryotherapy.

Focal treatment aims to treat the cancer-bearing portion of the prostate rather than the whole gland. This may reduce some treatment-related side effects in carefully selected men, but it requires accurate localisation of all clinically important disease.

MRI is used for:

• patient selection;
• treatment planning;
• directing confirmatory biopsy;
• monitoring the treated area;
• investigating possible residual or recurrent cancer.

Not every prostate cancer is suitable for focal treatment.

---

Why does the quality of the MRI matter?

The prostate cancer pathway increasingly depends on the MRI result. The scan’s technical quality is therefore extremely important.

Images may be degraded by:

• rectal gas;
• bowel movement;
• patient movement;
• hip replacements or other metalwork;
• unsuitable scanning parameters;
• inadequate spatial resolution;
• technical problems with diffusion imaging.

The PI-QUAL framework has been developed to assess whether the scan is of sufficient technical quality for reliable interpretation.

A high-quality prostate MRI service also depends on:

• radiologists with specialist prostate MRI experience;
• standardised scanning protocols;
• regular multidisciplinary discussion;
• comparison between MRI findings and biopsy results;
• audit of cancer detection and missed-cancer rates;
• communication between radiologists, urologists, oncologists and pathologists.

A score from a poor-quality scan may be less reassuring than the same score from an excellent-quality examination.

---

Can prostate MRI produce false-positive results?

Yes.

Several benign conditions can resemble prostate cancer on MRI, including:

• benign prostate enlargement;
• inflammation or prostatitis;
• scarring;
• bleeding after a previous biopsy;
• changes following surgery, radiotherapy or focal treatment.

This is one reason why MRI alone cannot diagnose prostate cancer.

A biopsy may show that a suspicious MRI lesion is benign. Although this can be frustrating, the MRI has still served an important purpose by identifying an area that required proper assessment.

---

Can prostate MRI miss cancer?

Yes, although modern prostate MRI is highly valuable.

Because a false-negative result is possible, specialists do not make biopsy decisions based on the MRI score alone.

The likelihood of missed significant cancer depends on:

• scan quality;
• radiologist expertise;
• tumour size;
• tumour location;
• tumour growth pattern;
• PSA density;
• the patient’s overall clinical risk.

Where clinical suspicion remains high, a biopsy may still be appropriate despite a normal or low-suspicion MRI.

---

What happens after the MRI?

The next step depends on the complete clinical picture rather than the MRI score alone.

Your specialist should review:

• the MRI report and images;
• the PSA level and previous results;
• prostate volume and PSA density;
• examination findings;
• urinary symptoms;
• previous biopsies;
• family history;
• ethnicity and inherited risk;
• age, health and personal preferences.

The possible next steps include:

1. No immediate biopsy, with planned PSA monitoring
   This may be appropriate when the MRI and clinical risk are reassuring.
2. Targeted transperineal biopsy
   This is commonly recommended for a suspicious MRI lesion.
3. Additional or repeat imaging
   This may be considered when the scan quality is limited or the result is uncertain.
4. Continued active surveillance
   Men with previously diagnosed low-risk cancer may continue monitoring if the findings remain reassuring.
5. Treatment planning
   If cancer has already been confirmed, the MRI may help guide surgery, radiotherapy or focal treatment.

---

Frequently asked questions

---

The importance of individual assessment

Prostate MRI has transformed the investigation of suspected prostate cancer. It allows clinicians to move away from relying only on PSA and relatively blind biopsy sampling towards a more individualised, image-directed pathway.

Its greatest value is not simply finding more cancers. It is helping to find the cancers that are most likely to matter, while allowing some men to avoid an unnecessary biopsy or treatment.

However, an MRI score should never be interpreted in isolation. A safe decision requires the scan to be considered alongside PSA density, examination findings, family history, previous investigations and the quality of the MRI itself.

For this reason, the most useful question is rarely simply:

“What is my MRI score?”

The more important question is:

“What does this MRI result mean when it is considered alongside all my other risk factors?”

---

About the author

Mr Neil Haldar is a Consultant Urological Surgeon with extensive experience in the investigation and treatment of prostate cancer. His practice includes raised PSA assessment, prostate biopsy, active surveillance, robotic prostatectomy and multidisciplinary prostate cancer care.

---

Important information

This article provides general information and should not replace an individual medical consultation. MRI findings and biopsy decisions should be interpreted by a suitably qualified specialist who has access to your complete clinical history, PSA results, examination findings and original images.

---

Key references

1. Ahmed HU, et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer: the PROMIS study. The Lancet. 2017.
2. Kasivisvanathan V, et al. MRI-targeted or standard biopsy for prostate cancer diagnosis: the PRECISION trial. New England Journal of Medicine. 2018.
3. Turkbey B, et al. Prostate Imaging Reporting and Data System Version 2.1. European Urology. 2019.
4. European Association of Urology. Guidelines on Prostate Cancer. Current edition.
5. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, NG131.
6. de Rooij M, et al. PI-QUAL version 2: an updated prostate MRI quality assessment system. 2024.

Have You Been Told Your PSA Is Raised or Your Prostate MRI Is Abnormal?

A raised PSA or an abnormal prostate MRI can understandably lead to uncertainty about what should happen next. The important question is not simply what your PSA, PI-RADS or Likert score is, but what it means when considered alongside your prostate size, PSA density, examination findings, family history and overall risk.

As a Consultant Urological Surgeon specialising in prostate cancer diagnosis and treatment, I can review your results, explain them clearly and help you decide on the most appropriate next step.

This may include:

• whether you need a prostate biopsy;
• whether a biopsy can safely be avoided or deferred;
• interpretation of a PI-RADS or Likert 3, 4 or 5 lesion;
• review of PSA density and PSA trends;
• discussion of transperineal targeted biopsy;
• further investigation of a persistently raised PSA despite a reassuring MRI;
• advice following a new diagnosis of prostate cancer.

Get a Clear Plan for What Happens Next

If you are concerned about a raised PSA, have received an abnormal prostate MRI result, or would like a specialist opinion before proceeding to biopsy or treatment, you can arrange a consultation with Mr Neil Haldar, Consultant Urological Surgeon.

Book a consultation to review your PSA and prostate MRI results and discuss the right next step for you.